Equity Research Orthopedic, Prosthetic & Surgical Appliances & Supplies

Should You Buy Cadre Holdings, Inc. Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Cadre Holdings, Inc. (CDRE) scores a robust 8.3/10 on our 32-signal Quality of Company framework. At the current market price of $29.17, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 2 of 12 CirclFi valuation models project upside for Cadre Holdings, Inc. (CDRE) at $29.17 — the model consensus leans bearish, with a Quality Score of 8.3/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 10 of 12 models suggest overvaluation — majority bearish
  • Quality Score: 8.3/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 18/100 — Minimal — healthy fundamentals
  • Fair Value Range: $0.89 – $41.96 (4628% spread)

Bullish Models

2 / 12

Bearish Models

10 / 12

Quality Score

8.3 /10

Excellent — top-tier fundamentals

Value Trap Risk

18 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

12 /13
Active Models

Avg. confidence: 51%

Investment Thesis

The Bull Case

Target: $41.96 (+43.8% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Cadre Holdings, Inc.'s score of 8.3/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $41.96 (+43.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $0.89 (-97.0%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $0.89 (-97.0%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +140.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

STE STERIS plc (Ireland)
9.7
ISRG Intuitive Surgical,
9.5
EW Edwards Lifesciences
8.9
MSA MSA Safety Incorpora
8.8
SNN Smith & Nephew SNATS
8.2

Valuation Divergence

Spread

4628%

Fair Value Range

$0.89 – $41.96

A 4628% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Markov DDM

$41.96 (+43.8%)

Most Bearish

EPV

$0.89 (-97.0%)

Key Risk Factors

Model Disagreement

4628% spread signals high variance in projections.

Bearish Consensus

10/12 models suggest overvaluation.

Macro/Sector Risk

Orthopedic, Prosthetic & Surgical Appliances & Supplies headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CDRE Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Cadre Holdings, Inc. at $29.17. 10/12 models flag overvaluation, composite fair value sits at $14.00 (-52.0%), and the risk-reward profile appears unfavorable. Quality at 8.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Cadre Holdings, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy CDRE stock right now?

Based on CirclFi's multi-model analysis, 2 of 12 models see upside for CDRE at $29.17. The models are divided, which means the investment case depends heavily on your assumptions about Cadre Holdings, Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Cadre Holdings, Inc.?

Key risks include: wide model disagreement (4628% spread), signaling high uncertainty; general market and sector-specific risks affecting Orthopedic, Prosthetic & Surgical Appliances & Supplies companies. Always diversify and consult a financial advisor.

How does CDRE compare to its competitors?

Among Orthopedic, Prosthetic & Surgical Appliances & Supplies peers, CDRE holds a Quality Score of 8.3/10. Comparable companies include STE (QOC 9.7), ISRG (QOC 9.5), EW (QOC 8.9). The relative ranking helps investors identify whether CDRE offers better fundamental quality than alternatives in the same sector.

Is CDRE a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CDRE's Quality Score of 8.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy CDRE at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $0.89 to $41.96. At $29.17, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CDRE.

View CDRE Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →